title: Tolerance of weekly paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin.
abstract: OBJECTIVE
  There are little data regarding safety and effectiveness of neoadjuvant chemotherapy (NACT) in patients who are considered unfit for receiving 3 weekly paclitaxel and carboplatin. The aim of this study was to study the toxicity and response rates of weekly paclitaxel and carboplatin as NACT in such cohort of patients.
  
  
  METHODS
  Study population included advanced ovarian cancer patients who were unlikely to tolerate 3 weekly paclitaxel and carboplatin and hence received weekly paclitaxel (80 mg/m2) and carboplatin AUC-2 as NACT. The data regarding the baseline characteristics, chemotherapy tolerance, completion rates, toxicity (CTCAE version 4.02), and radiological response rates are presented. SPSS version 16 was used for analysis. Descriptive statistics is presented.
  
  
  RESULTS
  Eleven patients received this schedule. Nine patients completed nine cycles of NACT. Except one, all patients completed NACT with an average relative dose intensity of >0.8. There was no chemotherapy-related mortality. Grade 3-4 life-threatening complications were seen in two patients. The post NACT response rate was 100%.
  
  
  CONCLUSIONS
  Weekly paclitaxel and carboplatin chemotherapy is safe and efficacious in patients who are unsuitable for 3 weekly paclitaxel and carboplatin chemotherapy schedules.
authors.affiliation: Department of Surgical Oncology, Malabar Cancer Center, Malabar Cancer Center, Moozhikkara, Kodiyeri, Thalassery, Kannur, Kerala, India.
authors.forename: S B
authors.initials: SB
authors.lastname: Dessai
authors.affiliation: Department of Radiation Oncology, Malabar Cancer Center, Malabar Cancer Center, Moozhikkara, Kodiyeri, Thalassery, Kannur, Kerala, India.
authors.forename: S
authors.initials: S
authors.lastname: Chakraborty
authors.affiliation: Department of Cancer Imaging, Malabar Cancer Center, Malabar Cancer Center, Moozhikkara, Kodiyeri, Thalassery, Kannur, Kerala, India.
authors.forename: Tvs
authors.initials: T
authors.lastname: Babu
authors.affiliation: Department of Oncopathology and Translational Medicine, Malabar Cancer Center, Malabar Cancer Center, Moozhikkara, Kodiyeri, Thalassery, Kannur, Kerala, India.
authors.forename: S
authors.initials: S
authors.lastname: Nayanar
authors.affiliation: Department of Division of Clinical Research and Biostatistics, Malabar Cancer Center, Malabar Cancer Center, Moozhikkara, Kodiyeri, Thalassery, Kannur, Kerala, India.
authors.forename: A
authors.initials: A
authors.lastname: Bhattacharjee
authors.affiliation: Department of Radiation Oncology, Malabar Cancer Center, Malabar Cancer Center, Moozhikkara, Kodiyeri, Thalassery, Kannur, Kerala, India.
authors.forename: J
authors.initials: J
authors.lastname: Jones
authors.affiliation: Department of Surgical Oncology, Malabar Cancer Center, Malabar Cancer Center, Moozhikkara, Kodiyeri, Thalassery, Kannur, Kerala, India.
authors.forename: S
authors.initials: S
authors.lastname: Balasubramanian
authors.affiliation: Department of Clinical Hematology and Medical Oncology, Malabar Cancer Center, Malabar Cancer Center, Moozhikkara, Kodiyeri, Thalassery, Kannur, Kerala, India.
authors.forename: V M
authors.initials: VM
authors.lastname: Patil
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin; D017239:Paclitaxel